Clinical Trial Details

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer (DESTINY-Lung06)

IRB Protocol Number
DESTINY LUNG

Clinical Trial Categories

  • Lung Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility:  Men and women 18+ years old, with diagnosis of non-squamous locally advanced unresectable or metastatic, has not received systemic anticancer therapy for advanced or metastatic non-squamous NSCLC.

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.